课题基金 / 基金详情

Characterization of clinically useful human monoclonal antibodies against cancers of digestive organ origin.

Characterization of clinically useful human monoclonal antibodies against cancers of digestive organ origin.
临床上有用的抗消化器官来源的癌症的人单克隆抗体的表征。
批准号:
15591376
负责人:
KODA Keiji
金额:
$1.34万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

KODA Keiji的其他基金

相似基金

相关文献

中文摘要
翻译
目的:SKI是一种人IgM单克隆抗体,可识别被称为AgSK1的抗原,该抗原被证明在人腺癌,特别是人类胃肠道恶性肿瘤中优先表达。本研究的目的是阐明AgSK1 mRNA表达在人类结直肠癌中的临床病理意义。方法:采用定量RT-PCR技术,研究40例结直肠癌患者切除标本中AgSK1 mRNA的表达水平。我们估计肿瘤组织值(T值)、非肿瘤组织值(N值)和T值与N值之比(T/N ratio)。为了进一步分析,我们将这些数据与临床病理特征进行了比较。结果:在淋巴结转移状态下,pN阳性状态的AgSK1 mRNA的t值水平往往高于pN阴性状态(P=0.076)。根据平均T值(8.032)或平均T/N比(1.549)将患者分为低表达组和高表达组。高表达组淋巴结转移阳性发生率显著高于对照组(T值P=0.021,T/N比P=0.024)。结论:肿瘤组织中AgSK1 mRNA的表达可能成为结直肠癌淋巴结转移的有用标志物和恶性潜在标志物。
英文摘要
PURPOSE : SKI, a human IgM monoclonal antibody recognizes the antigen, termed AgSK1 which was shown to be preferentially expressed by human adenocarcinomas, particularly human gastrointestinal malignancies. The aim of this study was to clarify the clinicopathological significance of AgSK1 mRNA expression in human colorectal cancer. METHODS : Using a quantitative RT-PCR, we studied the mRNA expression level of AgSK1 in the resected specimen of 40 patients with colorectal cancer. We estimated the tumor tissue value (T-value), nontumorous tissue value (N-value), and the ratio of T-value to N-value (T/N Ratio). For further analysis, we compared these data with the clinicopathological features. RESULTS : In the status of lymph node metastases, pN positive status tended to have a higher T-value level of AgSK1 mRNA than pN negative status (P=0.076). According to a mean T-value (8.032) or a mean T/N Ratio (1.549), we divided these patients into two groups, low expression group and high expression group. A high expression group showed a significantly higher frequency of positive lymph node metastases (T-value ; P=0.021,T/N Ratio ; P=0.024). CONCLUSION : AgSK1 mRNA expression in tumor tissue may become a useful marker for lymph node metastases and a malignant potential marker of colorectal cancer.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
Natural killer cell activity and distant metastasis in rectal cancers treated surgically with/without neoadjuvant cehmo-radiotherapy.
使用/不使用新辅助化疗的手术治疗直肠癌的自然杀伤细胞活性和远处转移。
DOI: --
发表时间: 2003
期刊: J Am Col Surg 197
影响因子: --
作者: [Keiji Koda, et al.]
通讯作者: et al.
Kondo E, Koda K, et al.: "Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for advanced colon cancer"Digestive Surg. 20. 445-451 (2003)
Kondo E、Koda K 等人:“术前自然杀伤细胞活性作为晚期结肠癌手术后远处转移的预后因素”消化外科。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Keiji Koda, et al.: "Natural killer cell activity and distant metastasis in rectal cancers treated surgically with/without neoadjuvant chemo-radiotherapy"J Am Col Surg. 197. 254-260 (2003)
Keiji Koda 等人:“使用/不使用新辅助化疗放疗进行手术治疗的直肠癌中的自然杀伤细胞活性和远处转移”J Am Col Surg。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: 10.1159/000072714
发表时间: 2003-01-01
期刊: DIGESTIVE SURGERY
影响因子: 2.7
作者: [Kondo, E, Koda, K, Miyazaki, M]
通讯作者: Miyazaki, M
共 10 条
    Investigation for the specific cancer immunotherapy using antigens recognized by a human natural antibody and the anti-idiotypic antibodies
    • 批准号:
      13671215
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2001
    • 负责人:
      KODA Keiji
    • 依托单位:
    A Basic Study for Cancer-Specific Immunotherapy using a Human Natural Antibody and its Anti-idiotypic Antibodies.
    海外基金